Pulmonx (LUNG) News Today $6.82 -0.05 (-0.73%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$6.82 0.00 (0.00%) As of 04/2/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Pulmonx Co. (NASDAQ:LUNG) Shares Sold by Pura Vida Investments LLCPura Vida Investments LLC trimmed its holdings in Pulmonx Co. (NASDAQ:LUNG - Free Report) by 24.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 387,200 shares of the company's stock after selling 122,575 sharesMarch 31 at 7:19 AM | marketbeat.comBrokerages Set Pulmonx Co. (NASDAQ:LUNG) Price Target at $13.36March 31 at 1:33 AM | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesPulmonx Co. (NASDAQ:LUNG - Get Free Report) has received an average rating of "Moderate Buy" from the nine research firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendationMarch 28, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III Sells 20,000 SharesPulmonx Co. (NASDAQ:LUNG - Get Free Report) Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $7.85, for a total transaction of $157,000.00. Following the completion of the transaction, the director now directly owns 991,974 shares in the company, valued at approximately $7,786,995.90. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.March 22, 2025 | marketbeat.comGlendon E. French III Sells 20,000 Shares of Pulmonx Co. (NASDAQ:LUNG) StockMarch 22, 2025 | insidertrades.comPrimecap Management Co. CA Reduces Holdings in Pulmonx Co. (NASDAQ:LUNG)Primecap Management Co. CA reduced its holdings in shares of Pulmonx Co. (NASDAQ:LUNG - Free Report) by 2.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,512,291 shares of the company's stock after selliMarch 19, 2025 | marketbeat.comD. Boral Capital Initiates Coverage of Pulmonx (LUNG) with Buy RecommendationMarch 11, 2025 | msn.comPulmonx (NASDAQ:LUNG) Now Covered by Analysts at D. Boral CapitalD. Boral Capital initiated coverage on Pulmonx in a report on Monday. They set a "buy" rating and a $17.00 target price on the stock.March 10, 2025 | marketbeat.comPulmonx initiated with a Buy at D. Boral CapitalMarch 10, 2025 | markets.businessinsider.comLake Street Keeps Their Buy Rating on Pulmonx (LUNG)March 8, 2025 | markets.businessinsider.comLake Street Keeps Their Buy Rating on Pulmonx (LUNG)March 8, 2025 | markets.businessinsider.comPulmonx Co. (NASDAQ:LUNG) CFO Mehul Joshi Sells 14,384 SharesPulmonx Co. (NASDAQ:LUNG - Get Free Report) CFO Mehul Joshi sold 14,384 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.12, for a total transaction of $102,414.08. Following the transaction, the chief financial officer now directly owns 113,986 shares of the company's stock, valued at $811,580.32. The trade was a 11.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.March 6, 2025 | marketbeat.comSteven S. Williamson Sells 27,689 Shares of Pulmonx Co. (NASDAQ:LUNG) StockPulmonx Co. (NASDAQ:LUNG - Get Free Report) CEO Steven S. Williamson sold 27,689 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.14, for a total value of $197,699.46. Following the completion of the sale, the chief executive officer now owns 194,342 shares in the company, valued at approximately $1,387,601.88. This represents a 12.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.March 6, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 5,779 SharesPulmonx Co. (NASDAQ:LUNG - Get Free Report) insider Geoffrey Beran Rose sold 5,779 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.13, for a total transaction of $41,204.27. Following the transaction, the insider now owns 285,278 shares in the company, valued at approximately $2,034,032.14. This trade represents a 1.99 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.March 6, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman Sells 22,355 SharesPulmonx Co. (NASDAQ:LUNG - Get Free Report) General Counsel David Aaron Lehman sold 22,355 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.65, for a total value of $171,015.75. Following the completion of the sale, the general counsel now directly owns 175,496 shares of the company's stock, valued at $1,342,544.40. The trade was a 11.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.March 6, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 5,779 SharesMarch 6, 2025 | insidertrades.comEDAP Appoints Glen French to Board of DirectorsMarch 3, 2025 | globenewswire.comPulmonx Co. (NASDAQ:LUNG) Given Consensus Rating of "Moderate Buy" by BrokeragesPulmonx Co. (NASDAQ:LUNG - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to tMarch 3, 2025 | marketbeat.comCiti Reaffirms Their Hold Rating on Pulmonx (LUNG)February 28, 2025 | markets.businessinsider.comPulmonx management to meet virtually with Lake StreetFebruary 27, 2025 | markets.businessinsider.comPulmonx Co. (NASDAQ:LUNG) Director Sells $459,150.84 in StockPulmonx Co. (NASDAQ:LUNG - Get Free Report) Director Glendon E. French III sold 55,453 shares of Pulmonx stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $8.28, for a total value of $459,150.84. Following the completion of the transaction, the director now owns 1,011,974 shares in the company, valued at approximately $8,379,144.72. The trade was a 5.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.February 25, 2025 | marketbeat.comInsider Selling: Pulmonx Co. (NASDAQ:LUNG) Director Sells 55,453 Shares of StockFebruary 25, 2025 | insidertrades.comPulmonx Corporation: Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial ResultsFebruary 21, 2025 | finanznachrichten.dePulmonx (LUNG) Gets a Buy from Piper SandlerFebruary 21, 2025 | markets.businessinsider.comPulmonx (NASDAQ:LUNG) Issues Quarterly Earnings ResultsPulmonx (NASDAQ:LUNG - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%.February 20, 2025 | marketbeat.comPulmonx projects 16%-18% constant currency growth for 2025 with key initiatives scalingFebruary 20, 2025 | seekingalpha.comPulmonx (LUNG) Receives a Buy from Stifel NicolausFebruary 20, 2025 | markets.businessinsider.comPulmonx Corporation (LUNG) Q4 2024 Earnings Call TranscriptFebruary 19, 2025 | seekingalpha.comPulmonx Reports Record Fourth Quarter and Full Year 2024 Financial ResultsFebruary 19, 2025 | globenewswire.comLake Street Remains a Buy on Pulmonx (LUNG)February 19, 2025 | markets.businessinsider.comPulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access DayFebruary 13, 2025 | globenewswire.comPulmonx (LUNG) Projected to Post Quarterly Earnings on WednesdayPulmonx (NASDAQ:LUNG) will be releasing earnings after the market closes on Wednesday, February 19, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=662965)February 12, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Pulmonx Co. (NASDAQ:LUNG - Get Free Report) have received a consensus rating of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy ratiFebruary 6, 2025 | marketbeat.comPulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025February 5, 2025 | globenewswire.comGlendon E. French III Sells 2,326 Shares of Pulmonx Co. (NASDAQ:LUNG) StockJanuary 22, 2025 | insidertrades.comPulmonx director French Glendon E. III sells shares worth $29,625January 22, 2025 | msn.comPulmonx Co. (NASDAQ:LUNG) Director Sells $15,188.78 in StockPulmonx Co. (NASDAQ:LUNG - Get Free Report) Director Glendon E. French III sold 2,326 shares of the business's stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $6.53, for a total value of $15,188.78. Following the sale, the director now directly owns 1,069,648 shares of the company's stock, valued at approximately $6,984,801.44. This trade represents a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.January 21, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Given Average Rating of "Moderate Buy" by BrokeragesShares of Pulmonx Co. (NASDAQ:LUNG - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. TheJanuary 12, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Pulmonx Co. (NASDAQ:LUNG - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy reDecember 18, 2024 | marketbeat.comPulmonx (LUNG) was downgraded to a Hold Rating at CitiDecember 17, 2024 | markets.businessinsider.comPulmonx (LUNG) Gets a Buy from Lake StreetDecember 12, 2024 | markets.businessinsider.comCitigroup Downgrades Pulmonx (LUNG)December 12, 2024 | msn.comWhat People Living With COPD or Emphysema Need to Know About Available TreatmentsDecember 11, 2024 | yahoo.comPulmonx (LUNG) Gets a Hold from Wells FargoDecember 11, 2024 | markets.businessinsider.comPulmonx's (LUNG) "Neutral" Rating Reiterated at CitigroupCitigroup restated a "neutral" rating and set a $7.50 price target (down previously from $17.00) on shares of Pulmonx in a report on Wednesday.December 11, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 188,926 Shares of Pulmonx Co. (NASDAQ:LUNG)Jacobs Levy Equity Management Inc. reduced its stake in Pulmonx Co. (NASDAQ:LUNG - Free Report) by 38.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 301,361 shares of the company's stock after selling 188,926 sDecember 8, 2024 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Shares Purchased by Fmr LLCFmr LLC boosted its stake in shares of Pulmonx Co. (NASDAQ:LUNG - Free Report) by 11.2% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 5,872,882 shares of the company's stock after acquiring an additional 591,859 shares during the period. Fmr LLC owned abDecember 8, 2024 | marketbeat.comPolar Asset Management Partners Inc. Makes New $893,000 Investment in Pulmonx Co. (NASDAQ:LUNG)Polar Asset Management Partners Inc. acquired a new stake in Pulmonx Co. (NASDAQ:LUNG - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 107,684 shares of the company's stock, valuedDecember 6, 2024 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Insider Sells $27,043.68 in StockDecember 5, 2024 | insidertrades.comAtom Investors LP Sells 92,305 Shares of Pulmonx Co. (NASDAQ:LUNG)Atom Investors LP cut its stake in Pulmonx Co. (NASDAQ:LUNG - Free Report) by 82.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,389 shares of the company's stock after selling 92,305 shares duriDecember 5, 2024 | marketbeat.com Remove Ads Get Pulmonx News Delivered to You Automatically Sign up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter. Email Address LUNG Media Mentions By Week LUNG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LUNG News Sentiment▼0.780.53▲Average Medical News Sentiment LUNG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LUNG Articles This Week▼32▲LUNG Articles Average Week Remove Ads Get Pulmonx News Delivered to You Automatically Sign up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Artivion News Today RxSight News Today National Vision News Today Pulse Biosciences News Today AxoGen News Today Bioventus News Today Embecta News Today CeriBell News Today Iradimed News Today Avanos Medical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LUNG) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LUNG Stock Free LUNG Stock Alerts